Frankfurt: German drugmaker Bayer said it filed for marketing approval in Europe for the use of eye drug Eylea as a treatment of diabetic macular oedema.
Bayer has said it expects Eylea, also known as VEGF Trap-Eye, to generate more than 1 billion euros ($1.35 billion) in peak annual sales.
The injection, which Bayer is co-developing with Regeneron, is already approved for other eye diseases. ($1 = 0.7392 euros).
Zee News App: Read latest news of India and world, bollywood news, business updates, cricket scores, etc. Download the Zee news app now to keep up with daily breaking news and live news event coverage.
